Allakos Inc. (NASDAQ:ALLK – Get Free Report) has received an average recommendation of “Moderate Buy” from the seven research firms that are currently covering the firm, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and five have issued a buy rating on the company. The average twelve-month price objective among analysts that have issued a report on the stock in the last year is $11.36.
Several research firms recently commented on ALLK. Barclays reduced their price target on shares of Allakos from $2.50 to $1.50 and set an “underweight” rating for the company in a research report on Tuesday, November 14th. JMP Securities reduced their price target on shares of Allakos from $11.00 to $10.00 and set a “market outperform” rating for the company in a research report on Tuesday, November 14th.
Allakos Trading Up 1.1 %
Hedge Funds Weigh In On Allakos
Large investors have recently made changes to their positions in the stock. Royal Bank of Canada increased its holdings in shares of Allakos by 91,137.5% in the 2nd quarter. Royal Bank of Canada now owns 7,299 shares of the company’s stock valued at $32,000 after purchasing an additional 7,291 shares in the last quarter. Tower Research Capital LLC TRC grew its stake in Allakos by 658.7% in the 3rd quarter. Tower Research Capital LLC TRC now owns 14,947 shares of the company’s stock valued at $34,000 after acquiring an additional 12,977 shares during the last quarter. Sei Investments Co. acquired a new stake in Allakos in the 2nd quarter valued at about $46,000. Inceptionr LLC acquired a new stake in Allakos in the 2nd quarter valued at about $49,000. Finally, Boulder Hill Capital Management LP acquired a new stake in Allakos in the 1st quarter valued at about $52,000. Hedge funds and other institutional investors own 84.64% of the company’s stock.
Allakos Inc, a clinical stage biopharmaceutical company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases. The company's lead monoclonal antibody is lirentelimab (AK002), which is in a Phase III study for the treatment of eosinophilic gastritis and/or eosinophilic duodenitis; a Phase II/III study for eosinophilic esophagitis; and a Phase II clinical study to atopic dermatitis and chronic spontaneous urticaria.
- Five stocks we like better than Allakos
- What Do S&P 500 Stocks Tell Investors About the Market?
- The most upgraded stocks in November have two things in common
- Stock Market Holidays 2022-2025 – Here’s When the NYSE and NASDAQ Will be Closed
- Monday.com rocked earnings like it’s the weekend
- What is a SEC Filing?
- Plan to own one retailer? Make it this one
Receive News & Ratings for Allakos Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allakos and related companies with MarketBeat.com's FREE daily email newsletter.